Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of the product for the past 12 months ended March 2024 were $51.8 million Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of the product for the past 12 months ended March 2024 were $51.8 million